KEAP1 and age-related macular degeneration: In the context of Keap1/Nrf2/ARE signaling pathway as a druggable target for AMD and other pathologies, various natural and synthetic Nrf2 activators have been recently tested in both in vitro and in vivo studies to evaluate their protective effects against different pro-oxidant stimuli (Pietrucha-Dutczak et al., 2018; Cui et al., 2019; Shao et al., 2019; Zhou et al., 2019; Fresta et al., 2020).